Cargando…
Modulation of mTOR signaling as a strategy for the treatment of Pompe disease
Mechanistic target of rapamycin (mTOR) coordinates biosynthetic and catabolic processes in response to multiple extracellular and intracellular signals including growth factors and nutrients. This serine/threonine kinase has long been known as a critical regulator of muscle mass. The recent finding...
Autores principales: | Lim, Jeong‐A, Li, Lishu, Shirihai, Orian S, Trudeau, Kyle M, Puertollano, Rosa, Raben, Nina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5331267/ https://www.ncbi.nlm.nih.gov/pubmed/28130275 http://dx.doi.org/10.15252/emmm.201606547 |
Ejemplares similares
-
mTOR and lysosome regulation
por: Puertollano, Rosa
Publicado: (2014) -
Pompe disease: from pathophysiology to therapy and back again
por: Lim, Jeong-A, et al.
Publicado: (2014) -
Atg5(flox)-Derived Autophagy-Deficient Model of Pompe Disease: Does It Tell the Whole Story?
por: Lim, Jeong-A, et al.
Publicado: (2017) -
Transcription factor EB (TFEB) is a new therapeutic target for Pompe disease
por: Spampanato, Carmine, et al.
Publicado: (2013) -
Enzyme Replacement Therapy Can Reverse Pathogenic Cascade in Pompe Disease
por: Meena, Naresh Kumar, et al.
Publicado: (2020)